Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

51.27 +1.57 (+3.17%)

Streaming Delayed Price Updated: 10:07 AM EDT, Apr 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area ↗

Today 6:50 EDT

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

Via The Motley Fool

Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position? ↗

April 07, 2026

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor.

Via The Motley Fool

Topics ETFs

CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? ↗

March 23, 2026

The gene-editing stock has been in a tailspin of late.

Via The Motley Fool

Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026

March 20, 2026

As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant...

Via Finterra

Topics Intellectual Property

Is CRISPR Therapeutics Stock a Buy Now? ↗

March 20, 2026

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Via The Motley Fool

3 Monster Stocks to Hold for the Next 10 Years ↗

March 10, 2026

They're names worth holding for far longer, but the coming decade could prove particularly fruitful for these companies.

Via The Motley Fool

Topics Artificial Intelligence

This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday ↗

March 10, 2026

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

Via The Motley Fool

Why Is CRSP Stock Falling Pre-Market Today? ↗

March 10, 2026

The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.

Via Stocktwits

RIVN Stock Gains 4% Pre-Market After TD Cowen Upgrade: Analyst Sees Strong Demand For Upcoming R2 Models ↗

March 10, 2026

The firm believes the new lineup could significantly expand Rivian's addressable EV market.

Via Stocktwits

Topics Electric Vehicles

Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of ↗

March 04, 2026

These two biotechs have a lot in common. Their differences are even more pronounced.

Via The Motley Fool

Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? ↗

March 02, 2026

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

March 01, 2026

Could these three stocks be Cathie Wood's next big winners?

Via The Motley Fool

Topics ETFs

Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? ↗

February 20, 2026

The past few years have been challenging for the biotech.

Via The Motley Fool

The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices ↗

February 20, 2026

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

Via The Motley Fool

Topics ETFs

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗

February 19, 2026

These biotech companies have catalysts ahead.

Via The Motley Fool

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows ↗

February 19, 2026

Via MarketBeat

Should You Buy Shares of CRISPR Therapeutics in February? ↗

February 18, 2026

The company could finally be ready to deliver on years of promise.

Via The Motley Fool

The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 ↗

February 13, 2026

2026 could be a big year for this company.

Via The Motley Fool

Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss) ↗

February 13, 2026

A sales partner offered a ray of hope that this company couldn't for itself.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

January 30, 2026

Opportunity knocks thrice for the iconic growth investor.

Via The Motley Fool

Topics Artificial Intelligence

Forget AI Stocks: This Biotech Could Cure What AI Can't Touch ↗

January 29, 2026

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

Via The Motley Fool

Topics Artificial Intelligence

Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗

January 29, 2026

Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits.

Via Stocktwits

Topics Artificial Intelligence ETFs Government

Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops ↗

January 27, 2026

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core...

Via Benzinga

2 Biotech Stocks That Could Soar This Year ↗

January 12, 2026

And, if all goes well, over the next five years as well.

Via The Motley Fool

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026? ↗

December 26, 2025

There are some risks to consider before jumping on the bandwagon.

Via The Motley Fool

The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy

December 24, 2025

On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),...

Via PredictStreet

Topics Economy

Is CRISPR Therapeutics Stock Yesterday's News? ↗

December 24, 2025

The biotech sells blood disorders treatment, Casgevy.

Via The Motley Fool

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗

December 23, 2025

All three companies' businesses are on the verge of long-term growth explosions.

Via The Motley Fool

Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? ↗

December 19, 2025

Next year could be crucial for the company as sales for its only approved treatment could take off.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.